Minsuk Kwon

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial

Biliary tract cancers (BTCs) are associated with poor outcomes despite recent incorporation of immune checkpoint inhibitors into first-line chemotherapy. Human epidermal growth factor receptor 2 (HER2) overexpression or amplification defines a therapeutically targetable subset of...

Real-world genomic landscape of FGFR2 amplifications and fusions in solid tumors: analysis of 4,953 patients using clinical-grade NGS

Fibroblast growth factor receptor 2 (FGFR2) alterations, including amplifications and fusions, are actionable oncogenic drivers in multiple cancers, but their prevalence and genomic features are not well defined. Between October 2019 and October 2024 at Samsung Medical Center, 4,...